Design of an optimized Wilms' tumor 1 (WT1) mRNA construct for enhanced WT1 expression and improved immunogenicity in vitro and in vivo

Molecular Therapy Nucleic Acids

Volumn 2, Issue NOV, 2013, Pages e134-

  Benteyn, Daphné ^a   Anguille, Sébastien ^b,c   Van Lint, Sandra ^a   Heirman, Carlo ^a   Van Nuffel, An M T ^a   Corthals, Jurgen ^a   Ochsenreither, Sebastian ^d   Waelput, Wim ^e   Van Beneden, Katrien ^a   Breckpot, Karine ^a   Van Tendeloo, Viggo ^c   Thielemans, Kris ^a   Bonehill, Aude ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DENDRITIC CELL LYSOSOME ASSOCIATED MEMBRANE PROTEIN; DNA; MESSENGER RNA; RNA VACCINE; WT1 PROTEIN; COMPLEMENTARY DNA; GAMMA INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; AUTOTOXICITY; CANCER IMMUNIZATION; CANCER PREVENTION; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); COMPUTER MODEL; CONTROLLED STUDY; CYTOPLASM; DNA SEQUENCE; DRUG DESIGN; ELECTROPORATION; FEMALE; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LYSOSOME; MOUSE; NEPHROBLASTOMA; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN ENGINEERING; PROTEINURIA; RNA IMMUNIZATION; RNA TRANSCRIPTION; TOXICITY; 3' UNTRANSLATED REGION; ANIMAL TISSUE; ANTIGEN EXPRESSION; CELLULAR DISTRIBUTION; CLONING; CODON USAGE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA BASE COMPOSITION; DNA VECTOR; ENDOPLASMIC RETICULUM; FLOW CYTOMETRY; IMMUNIZATION; IMMUNOREACTIVITY; OPEN READING FRAME; PROTEIN EXPRESSION; RNA VECTOR; T LYMPHOCYTE; TARGET CELL; WILD TYPE; ZINC FINGER MOTIF;

EID: 84892996730     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2013.54     Document Type: Article

References (53)

1. Boczkowski, D, Nair, SK, Snyder, D and Gilboa, E (1996). Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184: 465-472. (Pubitemid 26324100)
2. Nair, SK, Boczkowski, D, Morse, M, Cumming, RI, Lyerly, HK and Gilboa, E (1998). Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 16: 364-369. (Pubitemid 28164657)
3. Galluzzi, L, Senovilla, L, Vacchelli, E, Eggermont, A, Fridman, WH, Galon, J et al. (2012). Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 1: 1111-1134.
4. Van Nuffel, AM, Benteyn, D, Wilgenhof, S, Corthals, J, Heirman, C, Neyns, B et al. (2012). Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunol Immunother 61: 1033-1043.
5. Wilgenhof, S, Van Nuffel, AM, Corthals, J, Heirman, C, Tuyaerts, S, Benteyn, D et al. (2011). Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother 34: 448-456.
6. Benteyn, D, Van Nuffel, AM, Wilgenhof, S, Corthals, J, Heirman, C, Neyns, B et al. (2013). Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int 2013: 976383.
7. Van Lint, S, Goyvaerts, C, Maenhout, S, Goethals, L, Disy, A, Benteyn, D et al. (2012). Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 72: 1661-1671.
8. Weide, B, Pascolo, S, Scheel, B, Derhovanessian, E, Pflugfelder, A, Eigentler, TK et al. (2009). Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother 32: 498-507.
9. Weide, B, Carralot, JP, Reese, A, Scheel, B, Eigentler, TK, Hoerr, I et al. (2008). Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother 31: 180-188.
10. Bonehill, A, Tuyaerts, S, Van Nuffel, AM, Heirman, C, Bos, TJ, Fostier, K et al. (2008). Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther 16: 1170-1180. (Pubitemid 351737084)
11. Bonehill, A, Van Nuffel, AM, Corthals, J, Tuyaerts, S, Heirman, C, François, V et al. (2009). Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res 15: 3366-3375.
12. Cheever, MA, Allison, JP, Ferris, AS, Finn, OJ, Hastings, BM, Hecht, TT et al. (2009). The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15: 5323-5337.
13. Hohenstein, P and Hastie, ND (2006). The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet 15 Spec No 2: R196-R201. (Pubitemid 44446794)
14. Wilsher, M and Cheerala, B (2007). WT1 as a complementary marker of malignant melanoma: an immunohistochemical study of whole sections. Histopathology 51: 605-610. (Pubitemid 47572869)
15. Wagner, N, Panelos, J, Massi, D and Wagner, KD (2008). The Wilms' tumor suppressor WT1 is associated with melanoma proliferation. Pflugers Arch 455: 839-847. (Pubitemid 350265622)
16. Yang, L, Han, Y, Suarez Saiz, F, Saurez Saiz, F and Minden, MD (2007). A tumor suppressor and oncogene: the WT1 story. Leukemia 21: 868-876. (Pubitemid 46672061)
17. .Mundlos, S, Pelletier, J, Darveau, A, Bachmann, M, Winterpacht, A and Zabel, B (1993). Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues. Development 119: 1329-1341. (Pubitemid 23358597)
18. Sugiyama, H (2010). WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol 40: 377-387.
19. Oka, Y, Tsuboi, A, Taguchi, T, Osaki, T, Kyo, T, Nakajima, H et al. (2004). Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 101: 13885-13890. (Pubitemid 39298502)
20. Anguille, S, Van Tendeloo, VF and Berneman, ZN (2012). Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia 26: 2186-2196.
21. Van Driessche, A, Berneman, ZN and Van Tendeloo, VF (2012). Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist 17: 250-259.
22. Oka, Y, Elisseeva, OA, Tsuboi, A, Ogawa, H, Tamaki, H, Li, H et al. (2000). Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 51: 99-107. (Pubitemid 30150969)
23. Gao, L, Bellantuono, I, Elsässer, A, Marley, SB, Gordon, MY, Goldman, JM et al. (2000). Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95: 2198-2203. (Pubitemid 30167714)
24. Van Tendeloo, VF, Van de Velde, A, Van Driessche, A, Cools, N, Anguille, S, Ladell, K et al. (2010). Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA 107: 13824-13829.
25. Smits, EL, Anguille, S, Cools, N, Berneman, ZN and Van Tendeloo, VF (2009). Dendritic cell-based cancer gene therapy. Hum Gene Ther 20: 1106-1118.
26. Anguille, S, Lion, E, Smits, E, Berneman, ZN and van Tendeloo, VF (2011). Dendritic cell vaccine therapy for acute myeloid leukemia: questions and answers. Hum Vaccin 7: 579-584.
27. Van Nuffel, AM, Benteyn, D, Wilgenhof, S, Corthals, J, Heirman, C, Neyns, B et al. (2012). Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunol Immunother 61: 1033-1043.
28. Bonehill, A, Heirman, C, Tuyaerts, S, Michiels, A, Breckpot, K, Brasseur, F et al. (2004). Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol 172: 6649-6657. (Pubitemid 38669100)
29. De Keersmaecker, B, Heirman, C, Allard, S, Bonehill, A, Corthals, J, Thielemans, K et al. (2010). Lumenal part of the DC-LAMP protein is not required for induction of antigen-specific T cell responses by means of antigen-DC-LAMP messenger RNA-electroporated dendritic cells. Hum Gene Ther 21: 479-485.
30. Van Nuffel, AM, Benteyn, D, Wilgenhof, S, Pierret, L, Corthals, J, Heirman, C et al. (2012). Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients. Mol Ther 20: 1063-1074.
31. Fath, S, Bauer, AP, Liss, M, Spriestersbach, A, Maertens, B, Hahn, P et al. (2011). Multiparameter RNA and codon optimization: a standardized tool to assess and enhance autologous mammalian gene expression. PLoS ONE 6: e17596.
32. Turksma, AW, Bontkes, HJ, Ruizendaal, JJ, van den Heuvel, H, Scholten, KB, Santegoets, SJ et al. (2013). Increased cytotoxic capacity of tumor antigen specific human T cells after in vitro stimulation with IL21 producing dendritic cells. Hum Immunol 74: 506-513.
33. Holtkamp, S, Kreiter, S, Selmi, A, Simon, P, Koslowski, M, Huber, C et al. (2006). Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108: 4009-4017. (Pubitemid 44913269)
34. Van Driessche, A, Van de Velde, AL, Nijs, G, Braeckman, T, Stein, B, De Vries, JM et al. (2009). Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy 11: 653-668.
35. Bruening, W, Moffett, P, Chia, S, Heinrich, G and Pelletier, J (1996). Identification of nuclear localization signals within the zinc fingers of the WT1 tumor suppressor gene product. FEBS Lett 393: 41-47. (Pubitemid 26298225)
36. Coosemans, A, Wölfl, M, Berneman, ZN, Van Tendeloo, V, Vergote, I, Amant, F et al. (2010). Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma. Anticancer Res 30: 3709-3714.
37. Niksic, M, Slight, J, Sanford, JR, Caceres, JF and Hastie, ND (2004). The Wilms' tumour protein (WT1) shuttles between nucleus and cytoplasm and is present in functional polysomes. Hum Mol Genet 13: 463-471. (Pubitemid 38239797)
38. Van Driessche, A, Van de Velde, AL, Nijs, G, Braeckman, T, Stein, B, De Vries, JM et al. (2009). Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy 11: 653-668.
39. Kreiter, S, Selmi, A, Diken, M, Sebastian, M, Osterloh, P, Schild, H et al. (2008). Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J Immunol 180: 309-318.
40. Rock, KL, Farfán-Arribas, DJ and Shen, L (2010). Proteases in MHC class I presentation and cross-presentation. J Immunol 184: 9-15.
41. Apcher, S, Manoury, B and Fåhraeus, R (2012). The role of mRNA translation in direct MHC class I antigen presentation. Curr Opin Immunol 24: 71-76.
42. Apcher, S, Daskalogianni, C, Lejeune, F, Manoury, B, Imhoos, G, Heslop, L et al. (2011). Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translation. Proc Natl Acad Sci USA 108: 11572-11577.
43. Kuhn, AN, Diken, M, Kreiter, S, Vallazza, B, Türeci, Ö and Sahin, U (2011). Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics. RNA Biol 8: 35-43.
44. Depping, R, Schindler, SG, Jacobi, C, Kirschner, KM and Scholz, H (2012). Nuclear transport of Wilms' tumour protein Wt1 involves importins a and ß. Cell Physiol Biochem 29: 223-232.
45. Van der Bruggen, PS, Vigneron, N and Van den Eynde, B. Peptide database at 〈http://www.cancerimmunity.org/peptidedatabase/Tcellepitopes.htm〉
46. Reits, E, Griekspoor, A, Neijssen, J, Groothuis, T, Jalink, K, van Veelen, P et al. (2003). Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity 18: 97-108. (Pubitemid 36120691)
47. Kreiter, S, Selmi, A, Diken, M, Koslowski, M, Britten, CM, Huber, C et al. (2010). Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 70: 9031-9040.
48. Tuyaerts, S, Noppe, SM, Corthals, J, Breckpot, K, Heirman, C, De Greef, C et al. (2002). Generation of large numbers of dendritic cells in a closed system using Cell Factories. J Immunol Methods 264: 135-151. (Pubitemid 34615899)
49. Holtkamp, S, Kreiter, S, Selmi, A, Simon, P, Koslowski, M, Huber, C et al. (2006). Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108: 4009-4017. (Pubitemid 44913269)
50. .Michiels, A, Tuyaerts, S, Bonehill, A, Corthals, J, Breckpot, K, Heirman, C et al. (2005). Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther 12: 772-782. (Pubitemid 40668416)
51. Allard, SD, Pletinckx, K, Breckpot, K, Heirman, C, Bonehill, A, Michiels, A et al. (2008). Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef. Vaccine 26: 3735-3741.
52. Ho, WY, Nguyen, HN, Wolfl, M, Kuball, J and Greenberg, PD (2006). In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire. J Immunol Methods 310: 40-52. (Pubitemid 43375974)
53. Van Beneden, K, Geers, C, Pauwels, M, Mannaerts, I, Wissing, KM, Van den Branden, C et al. (2013). Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis. Toxicol Appl Pharmacol 271: 276-284.